Revance Therapeutics (NASDAQ: RVNC) reported Q1 EPS of ($1.08), $0.01 better than the analyst estimate of ($1.09). Revenue for the quarter came in at $13.3 million versus the consensus estimate of $10.98 million.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.